More Stories

Informist, Monday, Nov. 17, 2025

 

Please click here to read all liners published on this story

--Glenmark: Plan to launch 3-4 new pdts in US each quarter going forward 
--CONTEXT: Comments by Glenmark Pharma's mgmt in post-earnings investor call 
--Glenmark: Geopolitical uncertainties hit emerging market sales in Q2 
--Glenmark:Anti-allergy spray Ryalstris launch in 10-12 new mkts in some qrts 
--Glenmark: India business revenue seen at INR 48 bln in FY27 
--Glenmark:India ops to see revenue run rate of INR 11.5 bln-INR 12.0 bln/qtr 
--Glenmark: Aim is to be zero gross debt co in FY26 
--Glenmark: Expect FY27 revenue at INR 170 bln INR 180 bln 
--Glenmark: Aiming for 25?ITDA margin in coming years 
--Glenmark: Cash on books as on Sept 30 at INR 26.47 bln 
--Glenmark: Expect INR 80 bln of revenue in Oct-Mar 
--Glenmark: India inventory rationalisation impact close to INR 10 bln Q2 
--Glenmark: With strong growth, next 5-10 yrs to be transformational for co 
--Glenmark: Aim for 15% on-year consol sales growth going forward 

 

By Narayana Krishna and Adhithya Aji

 

HYDERABAD/MUMBAI – Glenmark Pharmaceuticals Ltd. on Monday said the next 5-10 years are going to be transformational for the company, as it is set to achieve strong growth in terms of revenue as well as profit led by an innovative product pipeline. The company is expected to achieve a revenue of INR 170 billion to INR 180 billion in 2026-27 (Apr-Mar), the management of Glenmark Pharma said in a post-earnings conference call with analysts. The company expects consolidated sales to grow 15% on year annually going forward.

 

On Friday, Glenmark Pharma reported a consolidated net profit of INR 6.1 billion, up more than 72% on year, led by the recognition of the first tranche from its deal with US pharmaceutical company AbbVie. The company's revenue for the quarter was up a little over 76% on year at INR 60.5 billion.

 

For Oct-Mar of FY26, Glenmark Pharma expects to clock in INR 80 billion of revenue, as the company expects India sales growth to be back in the growth trajectory led by secondary sales. For Apr-Sept, Glenmark Pharmaceuticals reported a consolidated net profit of INR 6.57 billion, down 5.4% on year. Its revenue, however, was up over 39% on year at INR 93.11 billion.

 

Glenmark's management said the company has initiated several changes in its overall way of operating and financials to improve margins and strengthen the balance sheet. "Actually, due to various operational constraints, we had a legacy pre-collection arrangement with the distributor across geography. These were high-cost arrangements, and as I said, 20% in some cases, which adversely affected our margins. With constraints now removed, we have discontinued these pre-collections, resulting in large increase in backups. The transition will support improved operating margins and help us to continue a strong margin trajectory going forward," the management said.

The company is expecting its earnings before interest, tax, depreciation, and amortisation margin to improve to over 25% in the coming years against the current 23% levels. The company also aims to bring its gross debt to zero by the end of FY26. As on Sept. 30, Glenmark has cash on books worth INR 26.47 billion. 

INDIA BUSINESS

Glenmark is expecting its India business to recover in Oct-Dec and to contribute INR 11.5 billion to INR 12.0 billion per quarter going forward. The company projected its India business revenue to be at INR 48 billion in FY27 led by new launches such as Tevimbra and Brukinsa, both used for cancer treatment. The company said these new products will drive growth for the next 2-3 years. The company is also preparing to launch Glucagon-Like-Peptie-1 products, which will add to the growth, management said.

For the September quarter, Glenmark reported an 87% on-year fall in its India sales at INR 1.7 billion due to the factors like cuts in goods and services tax rates and inventory adjustments in its primary sales. The company said its India sales saw nearly INR 10 billion hit due to the transition to the revised GST rates and inventory adjustments. The company expects additional growth from its India consumer care business, which was transferred to a separate company.

 
In the US, the company is planning to launch 3-4 new products every quarter going ahead. The company is preparing to leverage its strong capabilities in injectables and respiratory segments. Glenmark said it is waiting for US regulatory approval for two important nasal spray products. The company is also looking for approval for its generic Flovent in the US. Glenmark said 53 new drug applications were currently pending for approval with the US Food and Drug Administration, of which 22 product applications were under paragraph-IV category.

Glenmark is planning to launch its anti-allergic nasal spray Ryaltris in 10-12 new markets over the next few quarters. The company has so far submitted applications for approval of Ryaltris in 90 countries. Glenmark, in partnership with China's Grand Pharmaceutical (China) Co. Ltd., secured the approval for Ryaltris, and it is expected to be launched in FY27, the management said. Glenmark's management said geopolitical uncertainties impacted sales in some emerging markets during the September quarter.

 

At 1130 IST, Glenmark Pharmaceutical's shares traded at INR 1,888.10 on the National Stock Exchange, down 0.4% from the previous close.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Tanima Banerjee

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.